Comparison of Once and Twice Daily Dosing of Didanosine in Combination with Stavudine for the Treatment of HIV-1 Infection
暂无分享,去创建一个
[1] R. Pollard,et al. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team. , 1999, AIDS.
[2] P. Reiss,et al. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV‐1 infected individuals , 1998, AIDS.
[3] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.
[4] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.
[5] B. Clotet,et al. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy. , 1997, AIDS.
[6] M. Hirsch,et al. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. , 1996, The Journal of infectious diseases.
[7] J. Sommadossi. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2',3'-dideoxynucleoside analogues. , 1995, The Journal of infectious diseases.
[8] B. Larder,et al. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture , 1994, Antimicrobial Agents and Chemotherapy.
[9] D. Katzenstein,et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. , 1994, The Journal of infectious diseases.
[10] S. Broder,et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. , 1993, The Journal of clinical investigation.
[11] S. Broder,et al. Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[12] H. Liebman,et al. Didanosine in the treatment of AIDS and AIDS-related complex: a critical appraisal of the dose and frequency of administration. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] S. Kelley,et al. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily. , 1990, Reviews of infectious diseases.
[14] J. Ritter,et al. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. , 1990, The New England journal of medicine.